Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senti Biosciences ( (SNTI) ) has shared an update.
On April 1, 2026, Senti Biosciences announced plans for a holding company reorganization, expected to take effect by April 16, 2026, through a tax-free merger into a new Delaware subsidiary structure that will result in Senti Biosciences Holdings becoming the successor issuer. Each existing share of Senti Biosciences common stock will automatically convert into an equivalent share of Senti Biosciences Holdings common stock, with identical rights and no recognized gain or loss for U.S. federal income tax purposes for stockholders.
The reorganization will be executed under Delaware law without requiring a stockholder vote, and existing stock certificates and book entries will seamlessly represent the same number of new holding company shares. Following completion, the stock will continue trading uninterrupted on the Nasdaq Capital Market under the symbol SNTI with a new CUSIP, and Senti Biosciences Holdings will retain the same directors, officers, assets, and operations as before, though the company cautioned that timing or implementation could change.
The most recent analyst rating on (SNTI) stock is a Sell with a $0.75 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.
Spark’s Take on SNTI Stock
According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.
The score is held down primarily by very weak financial performance (zero recent revenue, large losses, and sustained cash burn) alongside heightened balance-sheet risk from sharply reduced equity and higher leverage. Technicals also lean bearish with the price below major moving averages and negative MACD. Valuation offers limited support given negative earnings and no stated dividend, while the recent lease restructuring is mixed but adds risk due to the letter-of-credit draw and GeneFab dependency.
To see Spark’s full report on SNTI stock, click here.
More about Senti Biosciences
Senti Biosciences, Inc. operates in the biotechnology sector, focusing on developing advanced cell and gene therapies using synthetic biology. The company targets serious and difficult-to-treat diseases, positioning itself within the innovative therapeutics market and listing its common stock on the Nasdaq Capital Market under the ticker symbol SNTI.
Average Trading Volume: 191,792
Technical Sentiment Signal: Sell
Current Market Cap: $25.29M
For an in-depth examination of SNTI stock, go to TipRanks’ Overview page.